Ixazomib citrate Chemical Properties

Density 

1.47±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO:100.0(Max Conc. mg/mL);193.38(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);193.38(Max Conc. mM)

form 

Solid

pka

3.59±0.10(Predicted)

color 

White to off-white

InChIKey

MBOMYENWWXQSNW-AWEZNQCLSA-N

SMILES

O1C(=O)C(CC(O)=O)(CC(O)=O)OB1[C@@H](NC(CNC(=O)C1=CC(Cl)=CC=C1Cl)=O)CC(C)C

Ixazomib citrate Usage And Synthesis

Uses

Ixazomib Citrate is a reversible boronic acid proteasome inhibitor.

Definition

ChEBI: A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of 2,2'-{2-[(1R)-1-amino-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diy }diacetic acid. A prodrug for ixazomib that is used in combination therapy for treatment of multiple myeloma.

Health effects

Ixazomib citrate is an N-capped dipeptidyl leucine boronic acid like bortezomib, and it is able to inhibit the chymotrypsin-like proteolytic site of the 20S proteasome.

Side effects

Common side effects of Ixazomib citrate include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative.

in vivo

Ixazomib citrate(1239908-20-3)Related Product Information

• MLN9708
• Ixazomib Impurity 1
• Acetamide, 2-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-
• (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid
• Repaglinide
• Bendamustine
• Ibrutinib
• Bortezomib
• Carfilzomib